Precipio presents poster on HemeScreen study

Precipio presented at the annual 2022 AMP conference a poster presentation of the results of a groundbreaking study, conducted in collaboration with faculty at the University of Pennsylvania. The study, expected to be published in detail early next year, demonstrates the superior results of Precipio’s HemeScreen MPN panel when compared to Sanger Sequencing. The study was co-authored by Dr. Christopher Sande, Resident Physician at University of Pennsylvania, Dr. Kojo Elenitoba-Johnson, formerly Professor of Pathology and Director of the Center for Personalized Diagnostics at the University of Pennsylvania and currently Chair of the Department of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center in New York City, and several members of Precipio’s scientific team. The goal of the study was to assess the accuracy of the HemeScreen technology by conducting blinded, side-by-side evaluation of patient samples with known results using two technologies. In the study, 982 patient samples were tested for the same genes using HemeScreen MPN panel, and Sanger Sequencing, considered the platform with the highest level of reliability and accuracy. The study demonstrated concordance of greater than 99% between the two technologies, with a variance of six samples where the HemeScreen assay detected a mutation, while the Sanger assay did not. This concordance, and the variance, are due to the increased sensitivity and specificity of the HemeScreen assay. This outcome demonstrates the superior performance of HemeScreen over Sanger in terms of diagnostic accuracy. As stated in the poster conclusions section, results demonstrated "exquisite accuracy, sensitivity and specificity of the HemeScreen MPN assay in detecting genetic variants observed in MPN". Furthermore, the "technology offers an opportunity for a low-cost approach with a simplified workflow for laboratories while providing a quick turnaround time, and accurate results".